A phase I/II trial of Dendritic cell based vaccine of CellxLife
Latest Information Update: 27 Jun 2024
At a glance
- Drugs Dendritic cell based vaccine CellxLife (Primary)
- Indications Ewing's sarcoma; Osteosarcoma
- Focus Adverse reactions
Most Recent Events
- 27 Jun 2024 New trial record
- 20 Jun 2024 According to a CellxLife media release, company is currently planning a basket trial for five other solid tumor indications. Also, company plans to initiate phase II trial with an orphan designation and significantly reducing the regulatory pathway for this promising immunotherapy.